Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects

Chera L. Maarouf, Thomas G. Beach, Charles H. Adler, Holly A. Shill, Marwan N. Sabbagh, Terence Wu, Douglas G. Walker, Tyler A. Kokjohn, Alex E. Roher

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


Objectives: Parkinson's disease (PD) afflicts approximately 1-2% of the population over 50 years of age. No cures or effective modifying treatments exist and clinical diagnosis is currently confounded by a lack of definitive biomarkers. We sought to discover potential biomarkers in the cerebrospinal fluid (CSF) of neuropathologically confirmed PD cases. Methods: We compared postmortem ventricular CSF (V-CSF) from PD and normal control (NC) subjects using two-dimensional difference gel electrophoresis (2D-DIGE). Spots exhibiting a 1.5-fold or greater difference in volume between PD patients and controls were excised from the two-dimensional gels, subjected to tryptic digestion and identification of peptides assigned using mass spectrometric/data bank correlation methods. Results: Employing this strategy six molecules: fibrinogen, transthyretin, apolipoprotein E, clusterin, apolipoprotein A-1, and glutathione-S-transferase-Pi, were found to be different between PD and NC populations. Discussion: These molecules have been implicated in PD pathogenesis. Combining biomarker data from multiple laboratories may create a consensus panel of proteins that may serve as a diagnostic tool for this neurodegenerative disorder.

Original languageEnglish (US)
Pages (from-to)669-676
Number of pages8
JournalNeurological research
Issue number7
StatePublished - Sep 2012


  • 2D-DIGE
  • Cerebrospinal fluid
  • Parkinson's disease
  • Proteomics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects'. Together they form a unique fingerprint.

Cite this